ViCentra Scales Kaleido Insulin Patch Pump Production, Triples Manufacturing Capacity
核心洞察
ViCentra (搜索) has begun commercial-scale production of Kaleido (搜索) insulin patch pump consumables at Phillips Medisize (搜索), tripling manufacturing capacity to support over 17,000 users.
The expanded production capacity positions ViCentra (搜索) to add thousands of new users across Germany, the Netherlands, and France through the second half of 2026.
The company has launched a new smartphone-controlled hybrid closed loop system combining Kaleido (搜索) with Diabeloop's DBLG2 algorithm and Dexcom (搜索) G7 CGM.
ViCentra (搜索) has achieved a significant operational milestone by beginning commercial-scale production of its Kaleido (搜索) insulin patch pump consumables at Phillips Medisize (搜索), a Molex (搜索) company and leading global medical technology contract development and manufacturing organization. The collaboration more than triples Kaleido consumables production capacity, with initial scale to support over 17,000 users.
The expanded manufacturing capacity positions ViCentra (搜索) to add thousands of new users across Germany, the Netherlands and France through the second half of 2026, with Germany representing the world's second-largest insulin pump market. Volume manufacturing at Phillips Medisize (搜索) anchors ViCentra's long-term unit economics and drives gross margin expansion.
Manufacturing Partnership Strengthens Supply Chain
"This is a very significant and crucial operational milestone for ViCentra (搜索)," said Tom Arnold, Chief Executive Officer of ViCentra. "Tripling capacity and improving margin performance allow ViCentra to bring Kaleido (搜索) to more people living with diabetes, reliably and at scale, across additional markets. With our new supply chain partner we now have the additional ability to continue to expand capacity."
Phillips Medisize (搜索) brings deep expertise in industrializing complex drug-delivery platforms, including insulin pumps and continuous glucose monitoring systems. The partnership combines ViCentra (搜索)'s user-centered technology with Phillips Medisize's global manufacturing scale and validated quality systems.
"ViCentra (搜索)'s design-led approach to wearable insulin delivery is exactly the type of innovation our global CDMO platform is built to industrialize," remarked David Thoreson, Vice President of Global Operations at Phillips Medisize (搜索). "Our capabilities in high-volume precision molding, assembly and rigorous validation position us to support a dependable supply of Kaleido (搜索) consumables across key European markets."
New Smartphone-Controlled System Launch
ViCentra (搜索) has also announced the commercial launch of its new smartphone-controlled hybrid closed loop system, with first commercial deliveries in Germany and the Netherlands planned for later this summer. The new system brings together Kaleido (搜索) with Diabeloop's self-learning DBLG2 algorithm and Dexcom (搜索) G7 Continuous Glucose Monitoring system to deliver a more streamlined hybrid closed loop experience.
The system enables hybrid closed loop therapy to be controlled directly from the user's smartphone, rather than a separate dedicated handset. Dexcom (搜索) G7 further enhances the experience with its smaller, all-in-one sensor and transmitter, making the overall system more streamlined and convenient to use.
"This is an important milestone for ViCentra (搜索) and an exciting step forward for people with diabetes in Germany and the Netherlands," said Arnold. "With Kaleido (搜索), DBLG2 and Dexcom (搜索) G7, we are making automated insulin delivery simpler, more flexible and easier to live with. It brings together smartphone control, the latest CGM technology and Kaleido's distinctive design in a way that fits more naturally into everyday life."
Kaleido Technology Platform
Kaleido (搜索) is described as the smallest, lightest, and most precise insulin patch pump in its class. It is designed to feel like personal technology, discreet, flexible, and customizable, while delivering highly accurate insulin dosing and hybrid closed loop therapy through integrations with partner algorithms and continuous glucose monitors.
The device is made from premium materials and features customizable aluminum shells in ten color options, enabling self-expression while providing glycemic control. It offers users flexibility in how and where they wear their pump, allowing people with diabetes to manage their therapy in a way that fits seamlessly into their daily lives.
Strong Commercial Momentum
This announcement builds on a year of strong momentum for ViCentra (搜索), including its $98 million Series D financing, doubling its user base to over 5,000 currently, expanding and strengthening its commercial and leadership teams, and the May 2026 launch of the smartphone-controlled Kaleido (搜索) system integrated with Diabeloop's DBLG2 algorithm.
With manufacturing now operating at commercial scale and unit economics strengthening, ViCentra (搜索) is positioned to accelerate adoption in its core European markets, expand into additional European countries, and continue preparations for U.S. market entry. Starting on Kaleido (搜索) today with Diabeloop's DBLG1 algorithm is the fastest path to Kaleido with DBLG2 and Dexcom (搜索) G7, allowing healthcare professionals to start therapy for people with diabetes now and transition them smoothly to the new system when it becomes available.